KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Sells $74,363.25 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko sold 7,627 shares of the company’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $9.75, for a total value of $74,363.25. Following the sale, the chief executive officer now owns 274,596 shares of the company’s stock, valued at $2,677,311. The trade was a 2.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

KalVista Pharmaceuticals Stock Performance

Shares of KALV opened at $9.44 on Wednesday. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.39 and a 52 week high of $16.88. The stock has a market capitalization of $466.52 million, a price-to-earnings ratio of -2.59 and a beta of 0.85. The stock has a fifty day moving average of $10.81 and a 200-day moving average of $11.80.

Analysts Set New Price Targets

Several brokerages recently weighed in on KALV. Needham & Company LLC restated a “buy” rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday.

Institutional Trading of KalVista Pharmaceuticals

A number of hedge funds have recently made changes to their positions in KALV. Vestal Point Capital LP increased its stake in shares of KalVista Pharmaceuticals by 73.9% in the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock valued at $46,320,000 after buying an additional 1,700,000 shares during the period. Great Point Partners LLC acquired a new position in KalVista Pharmaceuticals in the 2nd quarter valued at approximately $15,768,000. State Street Corp raised its stake in shares of KalVista Pharmaceuticals by 68.1% during the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock valued at $14,725,000 after acquiring an additional 515,179 shares during the last quarter. Emerald Advisers LLC lifted its holdings in shares of KalVista Pharmaceuticals by 29.8% during the third quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock worth $9,681,000 after purchasing an additional 192,091 shares during the period. Finally, Readystate Asset Management LP acquired a new position in shares of KalVista Pharmaceuticals during the third quarter worth $2,084,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).